ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 16, 2025
Dividend Increases/Decreases for the Week of May 16
Let's take a look at firms raising/lowering their dividends this week.
May 9, 2025
Dividend Increases/Decreases for the Week of May 9
Let's take a look at firms raising/lowering their dividends this week.
Apr 23, 2025
Tesla’s Revenue Falls in First Quarter, Pulls 2025 Outlook
Image Source: Tesla. Tesla’s non-GAAP net income attributable to common shareholders dropped 39% in the first quarter, while non-GAAP earnings per share fell 40%. Net cash provided by operating activities increased to $2.2 billion in the first quarter, while capital expenditures fell 46%, to $1.5 billion, resulting in free cash flow of $664 million in the period. Tesla’s cash and investments balance increased $0.4 billion at the end of the quarter, to $37 billion. Due to “the impacts of shifting global trade policy on the automotive and energy supply chains,” management pulled its 2025 guidance, noting that it will revisit it in its second quarter update. CEO Elon Musk said that his DOGE work is mostly done and beginning in May, his time allocated to DOGE will drop significantly. We like Tesla, but don’t include it in any newsletter portfolio.
Mar 7, 2025
Dividend Increases/Decreases for the Week of March 7
Let's take a look at firms raising/lowering their dividends this week.
Feb 11, 2025
Vertex Pharma Is One of Our Favorite Biotechs
Image: Vertex Pharma has performed quite well since the beginning of 2023. Looking to 2025, Vertex expects total revenue of $11.75-$12 billion, which includes expectations for continued growth in its cystic fibrosis portfolio, “including the U.S. launch of ALYFTREK, as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX." Cash and total marketable securities as of the end of last year were $11.2 billion, compared to $13.7 billion at the end of 2023 due to the cash consideration paid to acquire Alpine and share buybacks. Vertex had no traditional debt. We continue to like Vertex Pharma as a holding in the Best Ideas Newsletter portfolio.
Jan 14, 2025
KB Home’s Outlook for 2025 Better Than Expected
Image: KB Home’s shares have done well since the beginning of 2023. Looking to fiscal 2025, KB Home's housing revenue is expected in the range of $7.00-$7.5 billion, compared to the consensus forecast of $6.89 billion, with the average selling price in the range of $488,000-$498,000. Homebuilding operating income as a percentage of revenues is targeted at roughly 10.7%, which assumes no inventory-related charges. For the year, housing gross profit margin is targeted in the range of 20.0%-21.0% and assumes no inventory-related charges. Selling, general, and administrative expenses as a percentage of housing revenues is expected in the range of 9.6%-10.0%. We liked KB Home’s fourth quarter results and outlook for fiscal 2025 and what they imply with respect to the health of the housing market. KB Home doesn’t make the cut for any newsletter portfolio, however.
Jan 6, 2025
Target Expects Ho Hum Holiday Results
Image Source: Target. For the holiday fourth quarter, Target expects 1.5% comparable sales growth with GAAP and adjusted earnings per share in the range of $1.85-$2.45 (versus $2.64 consensus), translating to a full year expected GAAP and adjusted earnings per share range of $8.30-$8.90. The midpoint of the guidance range was down compared to its prior outlook in the range of $9.00-$9.70 and the consensus mark of $9.52. Target appears to be losing share against Walmart, Amazon and Costco, and there is no clear path to regaining it. Target’s shares yield 3.3% at the time of this writing.
Jan 1, 2025
Costco’s Business Humming Along Nicely, But Stock Is Not Cheap
Image Source: Costco. During the fiscal first quarter, Costco's membership income grew 7.8% year-over-year, while paid memberships grew 7.6% year-over-year, to 77.4 million. Total cardholders increased 7.2% year-over-year, to 138.8 million. Its worldwide renewal rate remained healthy at 90.4%. Net income for the quarter came in at $3.82, after excluding a $0.22 per share tax benefit related to stock-based compensation, beating the consensus forecast by a few pennies per share. Excluding discrete tax-related benefits occurring in both the most recently reported quarter and the same period last year, net income and diluted earnings per share advanced 9.9% and 9.8%, respectively. Costco’s fiscal first quarter was solid, but with the company trading at 50x forward earnings, we’re looking elsewhere.
Dec 13, 2024
Dividend Increases/Decreases for the Week of December 13
Let's take a look at firms raising/lowering their dividends this week.
Dec 11, 2024
Toll Brothers Ends Strongest Year Ever
Image Source: Toll Brothers. Looking to fiscal 2025, Toll Brothers' deliveries are expected in the range of 11,200-11,600 units with an average delivered price per home of $945,000-$965,000 and adjusted home sales gross margin expected at 27.25%. The company’s pace of deliveries is expected to be strong, but the company’s gross margin isn’t as strong as we would like, facing pressure from last year’s adjusted mark. SG&A, as a percentage of home sales revenue is expected in the range of 9.4%-9.5%, up from last year’s measure of 9.3%. Toll Brothers ended its fiscal fourth quarter with $1.3 billion in cash and cash equivalents and $2.7 billion in loans payable and senior notes. The company continues to return cash to shareholders in the form of buybacks and dividends. Though we don’t include Toll Brothers in any newsletter portfolio, the bellwether’s fiscal fourth quarter report indicates the housing market remains healthy.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.